MaxLinear (MXL) had the best month this year by a mid-cap US stock last month, returning 302%.

ASSET	MONTH	% RETURN
MaxLinear (MXL)	April 2026	301.99%
Xanadu Quantum Technologies Limited Class B Subordinate Voting Shares (XNDU)	April 2026	270.23%
Immunitybio (IBRX)	January 2026	209.41%
Erasca (ERAS)	January 2026	183.29%
Alumis (ALMS)	January 2026	150.87%
Aehr Test Systems (AEHR)	April 2026	137.07%
Organon (OGN)	April 2026	121.94%
Day One Biopharmaceuticals (DAWN)	March 2026	109.99%
Fastly, Inc Class A Common Stock (FSLY)	February 2026	108.05%
AXT (AXTI)	February 2026	107.16%
Innodata (INOD)	May 2026	106.1%
Apellis Pharmaceuticals (APLS)	March 2026	97.88%
Tango Therapeutics (TNGX)	March 2026	93.52%
Silicon Motion Technology (SIMO)	April 2026	91.56%
Sable Offshore (SOC)	March 2026	89.89%
POET Technologies (POET)	May 2026	87.52%
Nektar Therapeutics (NKTR)	February 2026	84.98%
Navitas Semiconductor (NVTS)	April 2026	83.33%
USA Rare Earth (USAR)	January 2026	82.57%
Maase (MAAS)	April 2026	79.3%
Acadia Healthcare (ACHC)	February 2026	75.06%
Babcock & Wilcox Enterprises (BW)	March 2026	72.22%
Valaris (VAL)	February 2026	71.47%
Enliven Therapeutics (ELVN)	January 2026	70.65%
Penguin Solutions (PENG)	April 2026	68.38%

Mid-cap stocks are treated as having a market cap between $2B and $10B.